Outcome
    Strong Evidence

    Omega-3 Fatty Acids for Triglyceride Reduction

    High-dose omega-3 is the most effective supplement for lowering triglycerides.

    Overview

    Of everything long-chain omega-3s are claimed to do, lowering triglycerides is the claim that holds up best. The relationship is dose-dependent and consistent: pooled trial data show roughly a 15% fall at typical study doses, rising toward 20-30% at 3-4 g daily of combined EPA and DHA, with the largest absolute reductions in people whose baseline is highest. The honest counterweight is that the same synthesis found little or no effect on mortality, coronary events or stroke. Omega-3 is a reliable way to move a lipid number and an unreliable way to move an outcome, and those two facts belong in the same sentence.

    Verdict

    Strong yes

    High-certainty evidence for dose-dependent triglyceride reduction of around 15% at typical doses and more at 3-4 g EPA+DHA. Cardiovascular event benefit is minimal in the same datasets.

    How It Works

    EPA and DHA cut the liver's triglyceride output. They downregulate SREBP-1c, the master switch for de novo lipogenesis, and activate PPAR-alpha, which pushes fatty acids into beta-oxidation rather than esterification. With less triglyceride assembled, fewer and smaller VLDL particles are secreted. On the clearance side, omega-3 intake raises lipoprotein lipase activity and reduces apolipoprotein C-III, an inhibitor of that enzyme. The net result is triglyceride-rich particles being both produced more slowly and removed more quickly — the physiological basis of the dose-response seen in trials.

    Pathways involved

    SREBP-1c downregulation
    PPAR-alpha activation
    Reduced hepatic VLDL secretion
    Increased lipoprotein lipase activity
    Lower apolipoprotein C-III
    Reduced de novo lipogenesis

    Dosing & Protocol

    ScenarioDoseFormTiming
    General health intake250-500 mg EPA+DHAStandard fish or algal oilDaily with a meal
    Mild hypertriglyceridaemia2-3 g EPA+DHAConcentrated oilSplit with meals
    Marked hypertriglyceridaemia3-4 g EPA+DHAPrescription-gradeClinician-directed
    Vegan route2-3 g EPA+DHA equivalentAlgal oilDaily with fat
    1. 1

      Work from EPA+DHA content· Before starting

      Capsule weight is not omega-3 content. Most 1 g capsules supply about 300 mg of EPA plus DHA.

    2. 2

      Titrate to 2-3 g EPA+DHA daily· Weeks 1-2

      Split across two meals containing fat to limit reflux and improve absorption.

    3. 3

      Cut the drivers alongside· Ongoing

      Alcohol, refined carbohydrate and uncontrolled glycaemia raise triglycerides substantially; addressing them often outperforms supplementation.

    4. 4

      Recheck a fasting lipid panel· Week 8-12

      At 8-12 weeks. If there is no movement at an adequate dose, look for a secondary cause.

    Dose is the whole story

    One standard capsule a day will not meaningfully change triglycerides. If lowering the number is the goal, the studied range is grams of EPA+DHA, and doses at the top of it warrant clinician involvement.

    Evidence

    The 2020 Cochrane review pooled 162,796 participants across randomised trials of long-chain omega-3 supplementation. Triglycerides fell dose-dependently by around 15%, a finding rated at high certainty and reproduced across trial populations and durations. The same review found little or no effect on all-cause mortality, cardiovascular mortality, coronary events or stroke, with small possible reductions in coronary heart disease mortality at low certainty. For this pairing that is the correct reading: the biomarker effect is dependable, and it should not be extrapolated into an event-prevention claim.

    Studies linked to this pairing.

    Omega-3 fatty acids for cardiovascular disease prevention

    Score: 10/10
    2020
    systematic_review
    n=162796

    Abdelhamid, A.S., Brown, T.J., Brainard, J.S.

    Increasing EPA and DHA has little or no effect on all-cause mortality and cardiovascular events.

    View source
    Best available evidence
    Cochrane review, 162,796 participants
    Typical effect size
    About 15% reduction, dose-dependent
    Time to effect
    4-12 weeks
    Certainty of evidence
    High for triglycerides, moderate to high for the null event findings

    Safety

    Atrial fibrillation risk rises with dose

    High-dose omega-3 trials at 3-4 g daily have shown a small but repeated increase in new-onset atrial fibrillation. Anyone with a history of arrhythmia should reach that dose only under clinical supervision.

    Common effects

    Fishy aftertaste and reflux
    Loose stools at gram doses
    Increased bruising at 3 g+
    Nausea if taken without food

    Interactions & Conflicts

    Interacts withSeverityMechanismAction
    Warfarin and DOACs
    moderate
    		Additive effect on platelet aggregation at high dosesDiscuss before exceeding 2 g EPA+DHA daily
    Antiplatelet agents
    moderate
    		Additive bleeding riskKeep to standard doses; report unusual bruising
    Antihypertensives
    low
    		Mild additive blood pressure reductionMonitor if close to target
    Statins and fibrates
    low
    		Complementary lipid effects, generally used togetherNo separation needed; monitor lipids

    References

    1. Abdelhamid AS et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2020
    2. Skulas-Ray AC et al. Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: AHA Science Advisory. Circulation. 2019

    Frequently Asked Questions

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.